US 11,878,973 B2
Bicyclic compounds and their uses
Vincent Bordas, Village-Neuf (FR); Jvan Brun, Muttenz (CH); Markus Furegati, Allschwil (CH); Jacques Hamon, Habsheim (FR); Jürgen Hans-Hermann Hinrichs, Schopfheim (DE); Philipp Holzer, Sissach (CH); Fatma Limam, Strasbourg (FR); Henrik Möbitz, Freiburg (DE); Sandro Nocito, Wölflinswi (CH); Simone Plattner, Weil am Rhein (DE); Niko Schmiedeberg, Riehen (CH); Joseph Schoepfer, Riehen (CH); Ross Sinclair Strang, Hagenthal le Bas (FR); and Frédéric Zecri, Brookline, MA (US)
Assigned to NOVARTIS AG, Basel (CH)
Filed by NOVARTIS AG, Basel (CH)
Filed on May 25, 2022, as Appl. No. 17/824,407.
Claims priority of application No. PCT/CN2021/096104 (WO), filed on May 26, 2021; and application No. PCT/CN2022/085537 (WO), filed on Apr. 7, 2022.
Prior Publication US 2023/0046859 A1, Feb. 16, 2023
Int. Cl. C07D 413/14 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01)
CPC C07D 413/14 (2013.01) [C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07B 2200/13 (2013.01)] 37 Claims
 
1. A compound, or a pharmaceutically acceptable salt thereof, selected from:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.
 
22. The compound, or a pharmaceutically acceptable salt thereof, according to claim 21, wherein the compound is in non-zwitterionic form.